|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further mechanistic studies show that CUDC-101 triggers caspase-dependent degradation of the promyelocytic leukemia-retinoic acid receptor alpha fusion protein.
|
31584454 |
2020 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The fusion oncogene, promyelocytic leukemia (PML)-retinoic acid receptor-α (RARα), is crucial for acute promyelocytic leukemia (APL) pathogenesis.
|
31654721 |
2020 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
APL is a model for oncogene-targeted therapies: <i>all-trans</i> retinoic acid (ATRA) and arsenic both target and degrade its ProMyelocytic Leukemia/Retinoic Acid Receptor α (PML/RARA) driver.
|
30674471 |
2019 |
|
Promyelocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, flourescence in situ hybridization (FISH) and reverse transcriptase polymerase chain reaction (RT-PCR) studies were negative for transcripts promyelocytic leukemia (<i>PML</i>) gene and retinoic acid receptor alpha (<i>RARA</i>) or <i>PML-RARA</i> fusion.
|
31371984 |
2019 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acute promyelocytic leukemia (APL) is commonly characterized by the fusion of retinoic acid receptor alpha (RARA) with promyelocytic leukemia (PML).
|
31447564 |
2019 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Arsenic trioxide (ATO) is another anti-cancer agent that promotes autophagy-dependent clearance of promyelocytic leukemia retinoic acid receptor alpha gene (PML-RARα) in APL cells.
|
31330838 |
2019 |
|
Promyelocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The promyelocytic leukemia (PML)-retinoic acid receptor α (RARA) fusion is hypothesized to serve a vital role in the pathogenesis of acute promyelocytic leukemia (APL), which results from a reciprocal translocation between chromosomes 15 and 17, t(15;17)(q24;q21).
|
30680014 |
2019 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
All-trans retinoic acid and arsenic trioxide treatment has been implemented for promyelocytic leukemia to target the PML-RARα fusion protein.
|
28521962 |
2018 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The promyelocytic leukemia (PML)/retinoic acid receptor-alpha (RARα) onco-fusion protein that is generated from t(15;17) chromosome translocation is crucial for the leukemogenesis of acute promyelocytic leukemia (APL) and is well documented as a transcriptional repressor.
|
30335887 |
2018 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, crocetin suppressed the expression of clinical marker promyelocytic leukemia/retinoic acid receptor-α ( PML/RARα) in NB4 and primary APL cells, and reduced the expression of histone deacetylase 1 ( HDAC1) in all leukemic cells.
|
30203596 |
2018 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present a case of an 18-year-old female who was diagnosed with AML (FLT3 (Fms like tyrosine kinase 3) and PML-RARA (promyelocytic leukemia-retinoic acid receptor alpha) translocation-negative) and after initial treatment with a standard induction regimen of cytarabine and daunorubicin (3+7 regimen), her bone marrow showed blast cells less than 5% and dense aggregates/sheets of atypical/immature mast cells with immunohistochemical stain CD117+ve and toluidine blue positive in mast cell aggregates.
|
30800544 |
2018 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The As2O3-mediated degradation of PML-RARA (promyelocytic leukemia-retinoic acid receptor-α) oncoprotein via the proteasome pathway appears to be critical for such distinguished sensitivity.
|
30338810 |
2018 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the role of promyelocytic leukemia/retinoic acid receptor α (PML/RARA) fusion protein is well recognized in acute promyelocytic leukemia (APL), its contribution to initiation and maintenance of leukemogenesis is not completely understood.
|
30266821 |
2018 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acute promyelocytic leukemia (APL) is characterized by the presence of the promyelocytic leukemia (PML)-retinoic acid receptor-α (RAR-α) fusion protein.
|
29344139 |
2017 |
|
Promyelocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, T152C was identified to be associated with promyelocytic leukemia-retinoic acid receptor α(PML-RARα) and French-American-British AML subtypes, with a tendency to occur in patients with AML-M3.
|
29113277 |
2017 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results therefore indicate that EGCG targets PML/RARα oncoprotein for degradation and potentiates differentiation of promyelocytic leukemia cells in combination with ATRA via PTEN.
|
28766684 |
2017 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
All-trans retinoic acid (ATRA) and/or arsenic trioxide (ATO) administration leads to granulocytic maturation and/or apoptosis of acute promyelocytic leukemia (APL) cells mainly by targeting promyelocytic leukemia/retinoic acid receptor alpha (PML/RARα).
|
28492552 |
2017 |
|
Promyelocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rare cases of promyelocytic leukemia-retinoic acid receptor α (PML-RARA) fusion without the reciprocal RARA-PML have been reported in cytogenetically normal samples.
|
28599418 |
2017 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nuclear localization signal retinoic acid receptor alpha(NLS-RARα), which forms from the cleavage of promyelocytic leukemia-retinoic acid receptor alpha(PML-RARα) protein by neutrophil elastase(NE), possesses an important role in the occurrence and development of acute promyelocytic leukemia(APL).
|
27499693 |
2016 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this project was to validate earlier time frames for the Abbott Molecular Vysis LSI promyelocytic leukemia (PML)/ retinoic acid receptor alpha (RARA) fluorescence in situ hybridization (FISH) probe (ASR 6-16 h).
|
25639817 |
2015 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epigenetic alterations have been described in several AMLs, and in some cases their origin has been studied in detail mechanistically (such as in acute promyelocytic leukemia, caused by the promyelocytic leukemia-retinoic acid receptor-α fusion protein).
|
25369368 |
2015 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The frequency and clinical significance of promyelocytic leukemia (PML)-retinoic acid receptor alpha (RARA) mutational status using Sanger sequencing were evaluated.
|
26294332 |
2015 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acute promyelocytic leukemia (APL) is characterized by the fusion of retinoic acid receptor alpha (RARA) with promyelocytic leukemia (PML) or, rarely, other gene partners.
|
25583766 |
2015 |
|
Promyelocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the combination of low concentrations of As4S4 and As3+ enhanced degradation of the promyelocytic leukemia-retinoic acid receptor α oncoprotein.
|
26110921 |
2015 |
|
Promyelocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The tumor suppressor promyelocytic leukemia (PML) was first identified as a component of PML-RARα fusion protein, one of the initiating cytogenetic abnormalities in acute promyelocytic leukemia.
|
24488785 |
2014 |